Athersys, Inc. Release: MultiStem® Cell Therapy May Overcome Major Challenges in Organ Transplantations
7/9/2013 9:32:03 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CLEVELAND, July 9, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that an international team of researchers has published study results in STEM CELLS Translational Medicine demonstrating that Multipotent Adult Progenitor Cells (MAPCTM) increase the long-term survival of organ transplants in instances when the cell donor is not related to the patient or the organ donor, and also appear to alleviate the need for long-term immune suppression. The preclinical research, conducted using a standard heart transplant model, also demonstrated that the transplanted organ retained its immunologically privileged state during a subsequent transplantation procedure into a naïve recipient, illustrating the durability of the effect. The risk of rejection and the requirement for long-term immunosuppression are key challenges in donor organ transplantations, which could be addressed by administering the clinical MAPC product, MultiStem®, to transplant patients.
Help employers find you! Check out all the jobs and post your resume.